EP1539931A4 - Differenzierungsmodulierende agentien und verwendungen dafür - Google Patents

Differenzierungsmodulierende agentien und verwendungen dafür

Info

Publication number
EP1539931A4
EP1539931A4 EP03735152A EP03735152A EP1539931A4 EP 1539931 A4 EP1539931 A4 EP 1539931A4 EP 03735152 A EP03735152 A EP 03735152A EP 03735152 A EP03735152 A EP 03735152A EP 1539931 A4 EP1539931 A4 EP 1539931A4
Authority
EP
European Patent Office
Prior art keywords
modulation agents
differentiation
differentiation modulation
agents
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03735152A
Other languages
English (en)
French (fr)
Other versions
EP1539931A1 (de
Inventor
Johannes Bernhard Prins
Louise Joyce Hutley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verva Pharmaceuticals Pty Ltd
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Priority to EP10184571A priority Critical patent/EP2267117A3/de
Publication of EP1539931A1 publication Critical patent/EP1539931A1/de
Publication of EP1539931A4 publication Critical patent/EP1539931A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP03735152A 2002-06-27 2003-06-27 Differenzierungsmodulierende agentien und verwendungen dafür Withdrawn EP1539931A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10184571A EP2267117A3 (de) 2002-06-27 2003-06-27 Differenzierungsmodulierende Wirkstoffe und Verwendungen dafür

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39213002P 2002-06-27 2002-06-27
US392130P 2002-06-27
PCT/AU2003/000826 WO2004003179A1 (en) 2002-06-27 2003-06-27 Differentiation modulating agents and uses therefor

Publications (2)

Publication Number Publication Date
EP1539931A1 EP1539931A1 (de) 2005-06-15
EP1539931A4 true EP1539931A4 (de) 2006-08-23

Family

ID=30000816

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10184571A Withdrawn EP2267117A3 (de) 2002-06-27 2003-06-27 Differenzierungsmodulierende Wirkstoffe und Verwendungen dafür
EP03735152A Withdrawn EP1539931A4 (de) 2002-06-27 2003-06-27 Differenzierungsmodulierende agentien und verwendungen dafür

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10184571A Withdrawn EP2267117A3 (de) 2002-06-27 2003-06-27 Differenzierungsmodulierende Wirkstoffe und Verwendungen dafür

Country Status (7)

Country Link
EP (2) EP2267117A3 (de)
JP (2) JP2005535629A (de)
CN (1) CN1678734B (de)
AU (2) AU2003236557B2 (de)
CA (1) CA2490261A1 (de)
NZ (1) NZ537208A (de)
WO (1) WO2004003179A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
JPWO2005093083A1 (ja) * 2004-03-29 2008-02-14 和久 前田 疾病予測方法、及びその利用方法
WO2006132447A1 (en) * 2005-06-10 2006-12-14 Primary Cell Co., Ltd. Method of inducing differentiation from visceral preadipocyte to visceral adipocyte
GB0520063D0 (en) * 2005-10-03 2005-11-09 Novartis Forschungsstiftung Methods for regulating metabolism and diagnosing disease
US7946916B2 (en) 2006-01-12 2011-05-24 Waterleaf Ltd. Variable payout wager games
CN101058801B (zh) * 2007-04-13 2010-05-19 中国人民解放军第二军医大学 促进人皮下脂肪干细胞分化成熟的方法及其应用
US8486904B2 (en) * 2007-10-01 2013-07-16 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
CN101259266B (zh) * 2008-04-14 2010-04-14 山东大学 一种前脂肪细胞异种疫苗及其制备方法和用途
WO2011130729A2 (en) 2010-04-16 2011-10-20 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
EP2797619A4 (de) * 2011-12-30 2015-07-08 Joslin Diabetes Center Inc Glypican-4 basierte zusammensetzungen und verfahren zur behandlung und diagnose von insulinresistenz
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US10251934B2 (en) 2013-04-16 2019-04-09 Orbsen Therapeutics Limited Syndecan-2 compositions and methods of use
US9925241B2 (en) 2013-10-21 2018-03-27 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−２のモジュレーターとその使用
WO2016172290A1 (en) * 2015-04-21 2016-10-27 Salk Institute For Biological Studies Methods of treating lipodystrophy using fgf-1 compounds
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
EP3652305A2 (de) 2017-07-14 2020-05-20 Orbsen Therapeutics Limited Verfahren zur isolierung und verwendung von stromalen stammzellen cd39
CN119386162A (zh) 2017-12-22 2025-02-07 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
JP2022509359A (ja) * 2018-10-26 2022-01-20 ガラニン、アイバン 生体内での最適な真皮白色脂肪組織形成を促進するための局所組成物および方法
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
CN117122587B (zh) * 2023-08-31 2025-09-19 上海市内分泌代谢病研究所 丙酮酸盐在治疗脂肪营养不良综合征中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (de) * 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoklonaler Antikörper gegen sauren FGF, seine Herstellung und Verwendung
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001049849A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
WO2001070977A2 (en) * 2000-03-22 2001-09-27 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
EP1202065A1 (de) * 2000-10-25 2002-05-02 Aventis Pharma S.A. NET, ein Transkriptionsfaktor aus der "TCF"-Familie, als Regulator von angiogener Expression
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424279A (en) 1890-03-25 Supporting wheel or pulley
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5648270A (en) 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5405975A (en) 1993-03-29 1995-04-11 Molecular Probes, Inc. Fluorescent ion-selective diaryldiaza crown ether conjugates
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5453517A (en) 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
ES2097925T3 (es) 1991-09-18 1997-04-16 Affymax Tech Nv Metodo para sintetizar diversas colecciones de oligomeros.
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
ATE199572T1 (de) 1995-11-21 2001-03-15 Univ Yale Unimolekulare segmentamplifikation und bestimmung
WO1999053927A1 (en) * 1998-04-17 1999-10-28 Trustees Of Tufts College Methods for treating and preventing insulin resistance and related disorders
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
DE60028054T2 (de) * 1999-09-08 2006-12-21 Genentech, Inc., South San Francisco Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
AU5056501A (en) * 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (de) * 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoklonaler Antikörper gegen sauren FGF, seine Herstellung und Verwendung
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2001049849A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
WO2001070977A2 (en) * 2000-03-22 2001-09-27 Amgen, Inc. Fibroblast growth factor receptor-like molecules and uses thereof
EP1202065A1 (de) * 2000-10-25 2002-05-02 Aventis Pharma S.A. NET, ein Transkriptionsfaktor aus der "TCF"-Familie, als Regulator von angiogener Expression
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
WO2004001059A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Heterocyclic inhibitors of kinases

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
COSIC IRENA ET AL: "In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 130, no. 1, 1994, pages 1 - 9, XP009062598, ISSN: 0300-8177 *
HAUNER H ET AL: "Effects of epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) on human adipocyte development and function.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION FEB 1995, vol. 25, no. 2, February 1995 (1995-02-01), pages 90 - 96, XP000198734, ISSN: 0014-2972, DOI: 10.1111/j.1365-2362.1995.tb01532.x *
KAWAGUCHI NOBUKO ET AL: "De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1062 - 1066, XP002370034, ISSN: 0027-8424 *
KRIEGER-BRAUER HEIDEMARIE I ET AL: "Antagonistic effects of different members of the fibroblast and platelet-derived growth factor families on adipose conversion and NADPH-dependent H-2O-2 generation in 3T3 L1-cells", BIOCHEMICAL JOURNAL, vol. 307, no. 2, 1995, pages 549 - 556, XP002370033, ISSN: 0264-6021 *
MILLER ET AL: "Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 6, 1 March 2000 (2000-03-01), pages 2260 - 2268, XP055072326, ISSN: 0270-7306 *
ORNITZ D M ET AL: "RECEPTOR SPECIFICITY OF THE FIBROBLAST GROWTH FACTOR FAMILY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 271, no. 25, 21 June 1996 (1996-06-21), pages 15292 - 15297, XP002919936, ISSN: 0021-9258, DOI: 10.1074/jbc.271.25.15292 *
R. T. BOTTCHER ET AL: "Fibroblast Growth Factor Signaling during Early Vertebrate Development", ENDOCRINE REVIEWS, vol. 26, no. 1, 1 February 2005 (2005-02-01), pages 63 - 77, XP055072332, ISSN: 0163-769X, DOI: 10.1210/er.2003-0040 *
RUSSELL T R ET AL: "CONVERSION OF 3T3 FIBROBLASTS INTO ADIPOSE CELLS: TRIGGERING OF DIFFERENTIATION BY PROSTAGLANDIN F2ALPHA AND I-METHYL-3-ISOBUTYL XANTHINE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 12, no. 73, 1 December 1976 (1976-12-01), pages 4516 - 4520, XP001079689, ISSN: 0027-8424, DOI: 10.1073/pnas.73.12.4516 *
SASAKI K ET AL: "Actions of acidic fibroblast growth factor fragments on food intake in rats", OBESITY RESEARCH, BATON ROUGE, LA, US, vol. 3, no. Suppl 5, 1 December 1995 (1995-12-01), pages 697S - 706S, ISSN: 1071-7323 *
SASAKI K ET AL: "EFFECTS OF FRIBROBLAST GROWTH FACTROS AND RELATED PEPTIDES ON FOOD INTAKE BY RATS", PHYSIOLOGY AND BEHAVIOR, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 56, no. 2, 1 January 1994 (1994-01-01), pages 211 - 218, XP000943197, ISSN: 0031-9384, DOI: 10.1016/0031-9384(94)90186-4 *
SCHMIDT ET AL: "Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 26, 1 September 1990 (1990-09-01), pages 15489 - 15495, XP055072329, ISSN: 0021-9258 *
See also references of WO2004003179A1 *
SERRERO G ET AL: "Prostaglandin F2 alpha inhibits epidermal growth factor binding to cellular receptors on adipocyte precursors in primary culture", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 212, no. 3, 26 July 1995 (1995-07-26), pages 1125 - 1132, XP008081146, ISSN: 0006-291X, DOI: 10.1006/bbrc.1995.2085 *

Also Published As

Publication number Publication date
AU2003236557B2 (en) 2009-10-01
CN1678734B (zh) 2012-12-12
JP2005535629A (ja) 2005-11-24
WO2004003179A1 (en) 2004-01-08
EP2267117A3 (de) 2011-07-13
AU2009251219A1 (en) 2010-01-28
JP2010215636A (ja) 2010-09-30
NZ537208A (en) 2009-02-28
AU2009251219B2 (en) 2013-01-10
AU2003236557A1 (en) 2004-01-19
EP2267117A2 (de) 2010-12-29
CN1678734A (zh) 2005-10-05
EP1539931A1 (de) 2005-06-15
CA2490261A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
EP1539931A4 (de) Differenzierungsmodulierende agentien und verwendungen dafür
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
EP1549332A4 (de) Modifizierte asialo-interferone und ihre verwendungen
DE60306753D1 (de) Zentrums-/umfangsumwickler und wickler
DK1572670T3 (da) 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
EP1692287A4 (de) Bakterielle virulenzfaktoren und verwendungen davon
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
EP1578947A4 (de) Gegen phospholipase a2 gerichtete antikörper und verwendungen davon
EP1538907A4 (de) Ftsz-hemmer und ihre verwendung
DE60326611D1 (de) N und dergleichen
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
EP1556029A4 (de) Thiomolybdat-analoga und ihre verwendungen
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DE50202025D1 (de) Stanznietverbindung und Halbhohlstanzniet
EP1699485A4 (de) Anti-hydrolysat-antikörper und ihre verwendungen
DE10390346D2 (de) Mikrofluidik-System
DE602004031826D1 (de) Fahrzeugzustandsanalysesystem, fahrzeug und fahrzeugzustandsverwaltungssystem
ATE370929T1 (de) Cyclohexyl-harnstoff-derivate
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
DE60318988D1 (de) Modulationsgerät und -verfahren
EP1633310A4 (de) Thiowolfram-analoga und ihre verwendungen
DE50303362D1 (de) Kraftaufnehmer
DE60330481D1 (de) Gelung
EP1641431A4 (de) Verwendungen von il-12 bei der hämatopoese
DE60331556D1 (de) Beschichtete kapillar-elektrophoreseröhren und system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076838

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20060725

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADIPOGEN PHARMACEUTICALS PTY LIMITED

17Q First examination report despatched

Effective date: 20090902

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VERVA PHARMACEUTICALS PTY

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101ALI20130703BHEP

Ipc: A61K 38/18 20060101AFI20130703BHEP

Ipc: C12N 5/077 20100101ALI20130703BHEP

Ipc: G01N 33/74 20060101ALI20130703BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076838

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103